Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series

Vickyanne Carruthers; Shelby Barnett; Rebecca Rees; Tasnim Arif; Olga Slater; Ramya Ramanujachar; Katie Johnson; Sarah Brown; Catherine Graham; G.A. Amos Burke; Gareth J. Veal

doi:10.1002/pbc.29722

Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series

Vickyanne Carruthers, Shelby Barnett, Rebecca Rees, Tasnim Arif, Olga Slater, Ramya Ramanujachar, Katie Johnson, Sarah Brown, Catherine Graham, G.A. Amos Burke, Gareth J. Veal^*

^*Corresponding author for this work

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

17 Downloads (Pure)

Abstract

Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations.

Original language	English
Article number	e29722
Number of pages	5
Journal	Pediatric Blood and Cancer
Volume	69
Issue number	7
Early online date	20 Apr 2022
DOIs	https://doi.org/10.1002/pbc.29722
Publication status	Published - Jul 2022

Bibliographical note

Funding Information:
The authors thank the clinical centres and the patient's families for allowing presentation of these cases for publication. This work was supported in part by Cancer Research UK, the Experimental Cancer Medicine Centre Network, the Little Princess Trust and the Sir Bobby Robson Foundation.

Publisher Copyright:
© 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.

Keywords

infantile myofibroma
neonate
pharmacokinetics
therapeutic drug monitoring
vinblastine

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.29722Licence: Creative Commons: Attribution (CC BY)

CarruthersV2022ClinicaFinal published version, 1.81 MBLicence: Creative Commons: Attribution (CC BY)

Cite this

@article{6f43afd06a49494e8bee65442bfe2780,

title = "Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series",

abstract = "Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations.",

keywords = "infantile myofibroma, neonate, pharmacokinetics, therapeutic drug monitoring, vinblastine",

author = "Vickyanne Carruthers and Shelby Barnett and Rebecca Rees and Tasnim Arif and Olga Slater and Ramya Ramanujachar and Katie Johnson and Sarah Brown and Catherine Graham and Burke, {G.A. Amos} and Veal, {Gareth J.}",

note = "Funding Information: The authors thank the clinical centres and the patient's families for allowing presentation of these cases for publication. This work was supported in part by Cancer Research UK, the Experimental Cancer Medicine Centre Network, the Little Princess Trust and the Sir Bobby Robson Foundation. Publisher Copyright: {\textcopyright} 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.",

year = "2022",

month = jul,

doi = "10.1002/pbc.29722",

language = "English",

volume = "69",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley",

number = "7",

}

TY - JOUR

T1 - Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients

T2 - A case series

AU - Carruthers, Vickyanne

AU - Barnett, Shelby

AU - Rees, Rebecca

AU - Arif, Tasnim

AU - Slater, Olga

AU - Ramanujachar, Ramya

AU - Johnson, Katie

AU - Brown, Sarah

AU - Graham, Catherine

AU - Burke, G.A. Amos

AU - Veal, Gareth J.

N1 - Funding Information: The authors thank the clinical centres and the patient's families for allowing presentation of these cases for publication. This work was supported in part by Cancer Research UK, the Experimental Cancer Medicine Centre Network, the Little Princess Trust and the Sir Bobby Robson Foundation. Publisher Copyright: © 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.

PY - 2022/7

Y1 - 2022/7

N2 - Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations.

AB - Infantile myofibroma is a rare, benign tumour of infancy typically managed surgically. In a minority of cases, more aggressive disease is seen and chemotherapy with vinblastine and methotrexate may be used, although evidence for this is limited. Chemotherapy dosing in infants is challenging, and vinblastine disposition in infants is unknown. We describe the use of vinblastine therapeutic drug monitoring in four cases of infantile myofibroma. Marked inter- and intrapatient variability was observed, highlighting the poorly understood pharmacokinetics of vinblastine in children, the challenges inherent in treating neonates, and the role of adaptive dosing in optimising drug exposure in challenging situations.

KW - infantile myofibroma

KW - neonate

KW - pharmacokinetics

KW - therapeutic drug monitoring

KW - vinblastine

UR - http://www.scopus.com/inward/record.url?scp=85129115439&partnerID=8YFLogxK

U2 - 10.1002/pbc.29722

DO - 10.1002/pbc.29722

M3 - Article

C2 - 35441483

AN - SCOPUS:85129115439

SN - 1545-5009

VL - 69

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 7

M1 - e29722

ER -

Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this